Atyr PHARMA’s (ATYR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Friday,Benzinga reports. They currently have a $35.00 price objective on the stock.

Several other analysts have also issued reports on the company. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Performance

Atyr PHARMA stock opened at $3.97 on Friday. Atyr PHARMA has a fifty-two week low of $1.42 and a fifty-two week high of $4.66. The firm’s fifty day moving average price is $3.65 and its 200-day moving average price is $3.06. The stock has a market cap of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. On average, equities research analysts expect that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ATYR. JPMorgan Chase & Co. boosted its position in Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth about $170,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth about $36,000. D.A. Davidson & CO. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth about $141,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA during the 4th quarter valued at about $144,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.